Physician profile
Douglas E Roberts
NPI 1508869926
$2,862.32
in general payments reported to CMS, 2019-2025
16 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $129 · 2021: $81.68 · 2022: $258 · 2023: $125 · 2024: $108 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $1,894 · Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $1,893.90 |
| Food and Beverage | $399.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $1,893.90 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $397.16 | 2019-2025 | Farxiga |
| Pfizer INC. | $121.26 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.10 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $66.58 | 2023-2024 | Lupkynis |
| Radius Health, INC. | $50.85 | 2022 | |
| Lilly USA, LLC | $45.40 | 2020-2021 | |
| Kerecis Limited | $35.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vertex Pharmaceuticals Incorporated | $26.69 | 2025 | |
| Glaxosmithkline, LLC. | $23.02 | 2025 | Arexvy, Shingrix |
| Abbott Laboratories | $20.77 | 2022 | |
| Esperion Therapeutics, INC. | $20.45 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.15 | 2022 | |
| Novo Nordisk INC | $18.06 | 2023 | Rybelsus, Ozempic |
| Ucb, INC. | $16.28 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $15.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.